Literature DB >> 26022003

Activation of Sirtuin-1 Promotes Renal Fibroblast Activation and Aggravates Renal Fibrogenesis.

Murugavel Ponnusamy1, Michelle A Zhuang1, Xiaoxu Zhou1, Evelyn Tolbert1, George Bayliss1, Ting C Zhao1, Shougang Zhuang2.   

Abstract

Although activation of sirtuin-1 (SIRT1) has been shown to protect the kidney from acute injury, its role in renal fibrosis remains controversial since both inhibition and activation of SIRT1 have been reported to attenuate renal fibrosis. To resolve this conflict, we further examined the effect of SIRT1 activators on the activation of renal interstitial fibroblasts and development of renal fibrosis in vivo and in vitro. In a murine model of renal fibrosis induced by unilateral ureteral obstruction, administration of SRT1720 (N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide), a potent activator of SIRT1, accelerated deposition of collagen fibrils and increased expression of fibroblast activation markers (α-smooth muscle actin [α-SMA], collagen I, and fibronectin) in the obstructive kidney of mice. In cultured rat renal interstitial fibroblasts (NRK-49F), exposure of cells to SRT1720 or YK-3-237 (B-[2-methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl]-boronic acid), another SIRT1 activator, also resulted in enhanced expression of α-SMA and fibronectin. Mechanistic studies showed that augmentation of renal fibrogenesis by SRT1720 is associated with elevated phosphorylation of epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor β (PDGFRβ). SRT1720 treatment also increased the phosphorylation of signal transducer and activator of transcription 3 and protein kinase B in the fibrotic kidney and NRK-49F cells. However, SRT1720 treatment did not affect expression of proliferating cell nuclear protein, a proliferation marker and activation of extracellular signal regulated kinase 1/2 in vitro and in vivo. These results indicate that SIRT1-activating compounds can provoke renal fibrogenesis through a mechanism involved in the activation of EGFR and PDGFR signaling pathways and suggest that long-term use of SIRT1 activators risks the development and progression of chronic kidney disease.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26022003      PMCID: PMC4518074          DOI: 10.1124/jpet.115.224386

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  46 in total

Review 1.  Regulation of PDGF and its receptors in fibrotic diseases.

Authors:  James C Bonner
Journal:  Cytokine Growth Factor Rev       Date:  2004-08       Impact factor: 7.638

Review 2.  Sirtuin activators and inhibitors.

Authors:  José M Villalba; Francisco J Alcaín
Journal:  Biofactors       Date:  2012-06-25       Impact factor: 6.113

3.  Epigenetic repression of matrix metalloproteinases in myofibroblastic hepatic stellate cells through histone deacetylases 4: implication in tissue fibrosis.

Authors:  Lan Qin; Yuan-Ping Han
Journal:  Am J Pathol       Date:  2010-09-16       Impact factor: 4.307

4.  Cell signaling. Stat acetylation--a key facet of cytokine signaling?

Authors:  John J O'Shea; Yuka Kanno; Xiaomin Chen; David E Levy
Journal:  Science       Date:  2005-01-14       Impact factor: 47.728

5.  Sirtuin biology and relevance to diabetes treatment.

Authors:  X Charlie Dong
Journal:  Diabetes Manag (Lond)       Date:  2012-05

Review 6.  SOCS regulation of the JAK/STAT signalling pathway.

Authors:  Ben A Croker; Hiu Kiu; Sandra E Nicholson
Journal:  Semin Cell Dev Biol       Date:  2008-07-30       Impact factor: 7.727

7.  SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1.

Authors:  Michelle Pacholec; John E Bleasdale; Boris Chrunyk; David Cunningham; Declan Flynn; Robert S Garofalo; David Griffith; Matt Griffor; Pat Loulakis; Brandon Pabst; Xiayang Qiu; Brian Stockman; Venkataraman Thanabal; Alison Varghese; Jessica Ward; Jane Withka; Kay Ahn
Journal:  J Biol Chem       Date:  2010-01-08       Impact factor: 5.157

8.  Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.

Authors:  Marco Di Pascoli; Marta Diví; Aina Rodríguez-Vilarrupla; Eugenio Rosado; Jorge Gracia-Sancho; Marina Vilaseca; Jaume Bosch; Joan Carles García-Pagán
Journal:  J Hepatol       Date:  2012-12-20       Impact factor: 25.083

9.  The histone deacetylase, SIRT1, contributes to the resistance of young mice to ischemia/reperfusion-induced acute kidney injury.

Authors:  Hong Fan; Hai-Chun Yang; Li You; Ying-Ying Wang; Wen-Juan He; Chuan-Ming Hao
Journal:  Kidney Int       Date:  2013-01-09       Impact factor: 10.612

10.  Phosphorylation of AKT: a mutational analysis.

Authors:  Jonathan R Hart; Peter K Vogt
Journal:  Oncotarget       Date:  2011-06
View more
  5 in total

Review 1.  TGF-β: the master regulator of fibrosis.

Authors:  Xiao-Ming Meng; David J Nikolic-Paterson; Hui Yao Lan
Journal:  Nat Rev Nephrol       Date:  2016-04-25       Impact factor: 28.314

2.  Identification of fibroblast activation-related genes in two acute kidney injury models.

Authors:  Weiming Deng; Xiangling Wei; Zhanwen Dong; Jinhua Zhang; Zhengyu Huang; Ning Na
Journal:  PeerJ       Date:  2021-03-18       Impact factor: 2.984

3.  Effect of the BRCA1-SIRT1-EGFR axis on cisplatin sensitivity in ovarian cancer.

Authors:  Da Li; Qi-Jun Wu; Fang-Fang Bi; Si-Lei Chen; Yi-Ming Zhou; Yue Zhao; Qing Yang
Journal:  Am J Transl Res       Date:  2016-03-15       Impact factor: 4.060

Review 4.  Application of Histone Deacetylase Inhibitors in Renal Interstitial Fibrosis.

Authors:  Ling Nie; Yong Liu; Bo Zhang; Jinghong Zhao
Journal:  Kidney Dis (Basel)       Date:  2020-03-26

5.  SIRT1 Protects Against Particulate Matter-Induced Oxidative Stress in Human Corneal and Conjunctival Epithelial Cells.

Authors:  Xiangzhe Li; Boram Kang; Youngsub Eom; Jingxiang Zhong; Hyung Keun Lee; Hyo Myung Kim; Jong Suk Song
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-09-01       Impact factor: 4.925

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.